Diane Berry, Ph.D.

Diane Berry, Ph.D. has served as Vice President, Global Policy, Government & Patient Affairs at Sarepta Therapeutics since December 2011. She engages policymakers at the federal, state, and local levels, as well as patient advocacy organizations, to advance critical policies related to newborn screening, regulatory policy, and reimbursement and access with a goal of expediting development and patient access to genetic-based therapies for rare diseases. Previously, Dr. Berry served in leadership roles for the federal government, across the legislative and executive branches, overseeing and implementing science and technology and public health activities. She served as a Subcommittee Staff Director and Senior Professional Staff Member for the U.S. House of Representatives Committee on Homeland Security and as Chief Scientist and Senior Biodefense Advisor at the Department of Homeland Security in the Office of Health Affairs. Dr. Berry was also a Senior Science Advisor at McKenna, Long, and Aldridge and a Science and Technology Policy Advisor and Fellow within the Department of Defense through the American Association for the Advancement of Science. She earned her Ph.D. in chemical engineering from Northwestern University and received her B.S. and M.S. in chemical/biochemical engineering from Tufts University.

Jaime Rubin Cahill, MA, MPH

Jaime Rubin Cahill, MA, MPH is the Vice President and Head of Health Economics and Outcomes Research (HEOR) at Vertex Pharmaceuticals. With over 15 years of HEOR experience, Jaime has been involved in dozens of Health Technology Appraisal (HTA) submissions, most recently to gain market access for Vertex’s portfolio of cystic fibrosis (CF) medicines. She has also led research activities that span across multiple disciplines within HEOR, with particular expertise in pharmacoeconomic modeling and evidence generation in rare diseases. Jaime has contributed to numerous publications in the area of health economics and outcomes research and presented her work at both pharmacoeconomic and clinical congresses. Prior to joining Vertex in 2012, Jaime held positions of increasing responsibility at HEOR consultancies DaVita Clinical Research and Optum, where she conducted outcomes research and led the development of pharmacoeconomic models for biopharma clients. She holds a bachelor’s degree in Economics from the University of Vermont, an MA in Economics from Tufts University, and an MPH in biostatistics from Boston University School of Public Health.

Robert Campbell, MD

Robert Campbell, MD, is ABMS certified in both Anesthesiology and Pain Management, and currently serves as President of Central Pennsylvania Anesthesia Partners.

After graduating Cum Laude from the University of Maryland with a BS degree in Biochemistry, Bob attended the University of Maryland School of Medicine and completed a residency in Anesthesiology and Pain Management at the Pennsylvania State University Medical Center in Hershey, PA. He has also worked as a physicist at the National Institute of Standards and Technology, and spent over a decade working at Lebanon Anesthesia Associates in Lebanon, PA.

In 2012, Bob co-founded and chaired Physicians Against Drug Shortages (PADS), which advocates for reform of the healthcare supply chain. He is active in many advocacy organizations, including Physicians for Reform, Patients Rising, Practicing Physicians of America, and Free2Care. He is Past President of the Pennsylvania Society of Anesthesiologists, and currently chairs its Committee on Legislative Affairs and Committee on Pain Management. He also serves as Pennsylvania Delegate to the American Society of Anesthesiologists.

Deanna Darlington

Advocacy Relations Director Deanna Darlington serves as the lead on access and value issues for patient advocacy relationships in the Amgen Washington, DC office. In this role, Deanna works closely with advocates on key policy issues that support dialogue and engagement specific to value and patient access to care. Prior to Amgen, Deanna oversaw the Onyx DC office and acted as Senior Director of Government Affairs. In this capacity, Deanna provided counsel to senior leadership regarding federal and state legislative activities, regulatory and health policy issues, and access issues that may impact patients and Onyx. Additionally, she was responsible for understanding the priorities of national advocacy and trade organizations in DC while identifying opportunities to partner with these groups on issues of mutual interest. Prior to joining Onyx, Deanna was Director of External Affairs at Novartis Oncology where she worked closely with the Oncology Executive Team to identify policy priorities and understand the concerns and interest of key external and internal stakeholders specific to oncology. Prior to Novartis, Deanna served as Director of Reimbursement and Policy at a number of Biotech companies. At these organizations, she was responsible for understanding issues that impact patient access as well as the development and oversight of Patient Assistance Programs (PAPs). Prior to joining the biotech and biopharmaceutical industry, Deanna served as the first Reimbursement Specialist for the American Society of Clinical Oncology, where she staffed the Clinical Practice Committee and developed the State Affiliate Program under the Association’s Public Policy arm.

Rafael Fonseca, MD

Dr. Rafael Fonseca is a specialist at the Mayo Clinic, clinical investigator for the Damon Runyon Cancer Research Fund, and an adjunct at the Translational Genomics Research Institute (TGen). Dr. Fonseca earned his medical degree at Universidad Anahuac, Mexico. He completed a residency in internal medicine at the University of Miami, and a fellowship in Hematology and Oncology at the Mayo Clinic Graduate School of Biomedical Sciences.

Dr. Fonseca’s clinical work focuses on diagnosing and treating plasma cell disorders. He also leads the multiple myeloma team in its effort to develop a better understanding of the disease and its impact on patients. In his laboratory, Dr. Fonseca has led his team of researchers in concentrating on the genetic nature of the clonal cells of plasma cell disorders. He also has expertise in myeloma bone disease, prognostic markers, and development of new therapies for the disease.

Dr. Fonseca has received numerous awards and honors, including the Young Investigator Award in Hematology, the Damon Runyon-Walter Winchell Clinical Investigator Award, and the International Waldenström Macroglobulinemia Research Award. Most notably, he is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at the institution. He has given many national and international presentations as a visiting professor, and has authored over 200 articles, book chapters, editorials, abstracts, and letters.

Brian Gill

During his 16 years at Celgene, Brian established global corporate communications and investor relations functions from the ground up, and eventually led those efforts, directly managing public relations and employee communications worldwide. Mr. Gill also led global communication strategies and tactics for multiple blockbuster disease-altering medicines in cancer and autoimmune disease, such as Revlimid and Pomalyst in multiple myeloma, Abraxane in pancreatic cancer, and Otezla in psoriatic diseases.

He was also the architect of Celgene’s value of medical innovation initiative, and contributed as a member of multiple strategic committees, including the Compliance Committee and the Digital Communications Committee. Brian also served on the communications committees for both PhRMA and BIO.

Prior to joining Celgene, Brian spent more than eight years as managing director for a leading corporate communication and investor relations firm in New York City, where he created and executed on corporate communications and investor relations programs for more than 40 global healthcare and biotech companies. He has also held senior management positions, both domestic and international, with leading healthcare and biotech companies, and gained capital markets experience on Wall Street as a market specialist for Paine Weber following the healthcare and biotech sectors.

Robert Goldberg, PhD

Robert Goldberg is Vice President and co-founder of the Center for Medicine in the Public Interest (CMPI), a non-profit organization that advocates for consumer access to public health innovations. He is also an adviser to Nonpareil, a biotech commercialization accelerator, as well as CEO and co-founder of Thrive HealthRx, a company that uses artificial intelligence to improve health outcomes. He also serves as a consultant for several biopharmaceutical companies on reimbursement, market access, and patient-centered value.

He has also advised HHS, the VA, and FDA on the limits of traditional approaches to data analysis currently used to assess public health benefits and risks. Goldberg’s work in this area focuses on generating reliable, real-world, consumer-level evidence. Prior to founding CMPI, Goldberg was Director of the Manhattan Institute’s Center for Medical Progress and Chairman of its 21st Century FDA Task Force that recommended ways to reduce the time and cost of getting innovative medicines to patients. Many of these recommendations were included in the 21st Century Cures Act.

Dr. Goldberg has published in peer-reviewed journals and also writes for The Wall Street Journal, Scientific American, The New York Post, Morning Consult, and Real Clear Health. He also contributes to, one of the mostly widely read blogs on medical innovation and drug regulation.

Jennifer Hinkel, MSc, DPhil Candidate

Jennifer Hinkel is a researcher and business leader in oncology outcomes, data, and health economics. Currently, she is VP for Strategic Collaborations at Caris Life Sciences, a DPhil (doctoral) candidate in Evidence Based Health Care at the University of Oxford, and on the Board of Lydion Research, a data economics science company. She also mentors a number of health and technology early-stage companies and founders. Her past roles include as a Senior Partner in a boutique market access consultancy as well as strategic, analytic, and commercial roles at Roche and Genentech in the US, Latin America, and Europe. Prior to entering the life sciences industry, Hinkel held roles in the non-profit and public sector including at National Comprehensive Cancer Network (NCCN), the Association for State and Territorial Health Officials (ASTHO), and in the office of a Parliamentary member of the United Kingdom House of Lords. Ms. Hinkel holds degrees from the Georgia Institute of Technology (BS International Affairs) and the London School of Economics (MSc International Health Policy). She has lectured in Health Systems and Health Economics at Penn State University and Arcadia University, holds patents in health care technology, and has published numerous articles and abstracts related to market access and oncology health services research. As a survivor of Stage III Hodgkin Lymphoma, Ms. Hinkel has a special interest in oncology innovation as a cancer survivor. To support the broader survivor and oncology community, Ms. Hinkel founded Resilience Racing, the first all-cancer-survivor sailing team, and also launched the 40 Under 40 in Cancer annual awards program.

Aaron N. Krupp

Aaron N. Krupp, Senior Director of Government Affairs & Policy for Global Blood Therapeutics (GBT), has more than 15 years of experience in healthcare legislative and policy issues. Mr. Krupp, who joined GBT in 2019, helps lead the company’s government affairs and policy function. He currently focuses his efforts on ensuring access to new therapies to treat sickle cell disease in Medicare and Medicaid. He also advises and leads efforts on numerous other critical biotechnology issues.

Prior to joining GBT, Mr. Krupp was Director of Therapeutic Area Policy for Astellas. Before Astellas, he spent more than 8 years with AbbVie and Abbott.

Mr. Krupp received a B.A. in Criminal Justice from Indiana University and a J.D. from the John Marshall Law School.

Michael Miller, MD

Dr. Michael Miller is a health care and life sciences expert. He graduated magna cum laude from Williams College with a B.A. in chemistry, and received his M.D. from the Yale University School of Medicine. For more than 25 years, Dr. Miller has been supporting the development, reimbursement, and appropriate use of clinical and scientific innovations to expand access to better care and improve outcomes.

In his work as a health care and life sciences expert, Dr. Miller has worked with large and small organizations and private companies, as well as with governmental organizations, including the National Governors Association, the U.S. House of Representatives, the U.S. Senate, the National Institutes of Health, and the White House’s Office of Management and Budget. His work has covered a broad range of issues, including new financing and delivery models, reimbursement practices, government programs, telemedicine, IP protection, and innovations for specific clinical conditions and populations to achieve measurable clinical and economic improvements. Clinical areas have included autoimmune diseases, cancer, cardiovascular diseases, COPD, diabetes, infectious diseases, maternal and child health, mental illnesses, musculoskeletal conditions, neurodegenerative diseases, osteoporosis, pain and opioids, public health, prevention, and women’s health.

In addition, Dr. Miller has spoken and written extensively about the interactions across the health care delivery, financing, research, and public health systems, including his “Drug Pricing Principles” chapter in The Entrepreneur’s Guide to a Biotech Startup.

Nathan Yates

Nathan Yates is the founder of ForwardView Consulting, and is an entrepreneur, economic and financial analyst, and Spinal Muscular Atrophy (SMA) patient advocate. Prior to founding a consultancy, Nathan worked for an independent equity research firm covering the industrial and energy sectors. He holds a Bachelor’s degree in Economics and Finance and a Master’s degree in Finance from Southern New Hampshire University, graduating summa cum laude and being named Outstanding Student in his area of focus. Nathan previously taught economics and finance at his alma mater as an adjunct professor and held a faculty leadership role. Nathan’s piece published in May 2019 in STAT News, entitled “I have spinal muscular atrophy. Critics of the $2 million new gene therapy are missing the point,” brought his voice and perspective as both a patient and a finance/economics expert to the debate on gene therapy pricing and value.